The inaugural Stanford Cancer Institute Advances in Mass Spectrometry Enabled Drug Discovery symposium on October 29, 2024 will bring together leading experts in academia and industry to explore current challenges and opportunities and recent achievements across diverse applications in drug development. 

This field has revolutionized ligand and target discovery by enabling the detection of interactions proteome-wide. Chemoproteomic techniques targeting reactive residues have grown and expanded the scope of covalent ligand discovery. Mass spectrometry instrumentation continues to improve, deepening proteomic coverage, accuracy, and sensitivity while becoming more accessible.

The symposium is open to Stanford faculty, students, and postgraduates, as well as those outside of Stanford who are interested in diving into the cutting-edge world of proteomics. Join us for this all-day dynamic learning experience to discuss the exciting progress in mass spectrometry-based proteomics.